Report overview
This report contains market size and forecasts of Tumor Immunity Therapy in Global, including the following market information:
Global Tumor Immunity Therapy Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Tumor Immunity Therapy market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Immune Checkpoint Inhibitor Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tumor Immunity Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Immunity Therapy Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Type, 2022 (%)
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Global Tumor Immunity Therapy Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Tumor Immunity Therapy Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Tumor Immunity Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Immunity Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Tumor Immunity Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
